- Home
- JYD vs CNSP Comparison
JYD vs CNSP Comparison
Compare JYD & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JYD | CNSP |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2M | 8.5M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | JYD | CNSP |
|---|---|---|
| Price | $0.93 | $5.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 105.0K | 6.8K |
| Earning Date | 05-15-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $1.90 |
| 52 Week High | $6.85 | $10.59 |
Technical Indicators
Market Signals| Indicator | JYD | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 48.71 | 54.00 |
| Support Level | $0.66 | $4.63 |
| Resistance Level | $1.07 | $5.72 |
| Average True Range (ATR) | 0.11 | 0.41 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 15.05 | 63.43 |
Price Performance
Historical ComparisonAbout JYD Jayud Global Logistics Limited
Jayud Global Logistics Ltd is an end-to-end supply chain solution provider in China, with a focus on providing cross-border logistics services. The company offers freight forwarding services, fragmented logistics, and chartered airline freight services, supply chain management, and other value-added services.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.